BML Capital Management LLC Has $394,000 Holdings in Forte Biosciences, Inc. (NASDAQ:FBRX)

BML Capital Management LLC decreased its position in Forte Biosciences, Inc. (NASDAQ:FBRX) by 96.0% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 70,468 shares of the company’s stock after selling 1,691,234 shares during the quarter. Forte Biosciences comprises approximately 0.2% of BML Capital Management LLC’s investment portfolio, making the stock its 26th biggest position. BML Capital Management LLC’s holdings in Forte Biosciences were worth $394,000 at the end of the most recent reporting period.

Analyst Ratings Changes

Separately, Chardan Capital restated a “buy” rating and set a $3.00 target price on shares of Forte Biosciences in a research note on Monday, August 19th.

Forte Biosciences Price Performance

Shares of FBRX traded up $0.02 during trading hours on Tuesday, hitting $5.42. The stock had a trading volume of 378 shares, compared to its average volume of 4,389. Forte Biosciences, Inc. has a 1-year low of $4.11 and a 1-year high of $21.25. The firm has a market capitalization of $7.91 million, a P/E ratio of -0.30 and a beta of 0.04. The firm has a 50 day simple moving average of $5.64 and a 200-day simple moving average of $2.17.

Forte Biosciences (NASDAQ:FBRX) last posted its quarterly earnings data on Wednesday, August 14th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.11). Equities analysts predict that Forte Biosciences, Inc. will post -22.5 EPS for the current fiscal year.

Forte Biosciences Company Profile

Forte Biosciences, Inc operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc is headquartered in Dallas, Texas.